Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SubQSA: Isatuximab SC-OBDS + Kd in RRMM
NCT06356571Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Mar 2025; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06356571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356571.